Belimumab

Phase 3Recruiting

0 views this week 0 watching⚡ Active📊Featured in Mid-Cap Catalyst Watch

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Connective Tissue Diseases

Conditions

Connective Tissue Diseases

Trial Timeline

Dec 12, 2024 → Dec 27, 2029

NCT ID

NCT06716606

About Belimumab

Belimumab is a phase 3 stage product being developed by ICON plc. for Connective Tissue Diseases. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06716606. Target conditions include Connective Tissue Diseases.

What happened to similar drugs?

1 of 2 similar drugs in Connective Tissue Diseases were approved

Approved (1) Terminated (1) Active (0)

✅SildenafilPfizerApproved

❌Placebo capsules + Bardoxolone methyl capsulesBiogenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06716606	Phase 3	Recruiting	Dec 12, 2024	Dec 27, 2029	Connective Tissue Diseases

Competing Products

2 competing products in Connective Tissue Diseases

See all competitors

Product	Company	Stage	Hype Score
Sildenafil	Pfizer	Approved	43
Placebo capsules + Bardoxolone methyl capsules	Biogen	Phase 3	29